시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 만성 염증성 탈수초성 다발신경병증(CIDP) 시장 보고서(2025년)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025
상품코드 : 1720754
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,278,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,075,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,872,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

만성 염증성 탈수초성 다발신경병증(CIDP) 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연간 평균 성장률(CAGR) 8.1%로 성장할 전망이며, 31억 1,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 세계 인구의 고령화, 희귀질환 및 자가면역 질환에 대한 주목 증가, 헬스케어 접근성 개선, 환자 옹호 및 의식 향상 캠페인 증가, 헬스케어 인프라의 진보로 인한 것으로 예측됩니다. 주요 동향으로는 만성 염증성 탈수초성 다발신경병증의 유병률 상승, 치료 선택의 진전, 연구개발 활동의 확대, 바이오시밀러 치료의 출현, 맞춤형 의료 어프로치의 개발 등을 들 수 있습니다.

헬스케어 지출 증가는 만성 염증성 탈수초성 다발신경병증(CIDP) 시장의 성장을 가속할 것으로 예측됩니다. 의료 지출 증가는 의료 인프라에 대한 투자, 첨단 치료에 대한 수요 증가, 보험 적용 범위 확대, 의료 접근을 개선하기 위한 정부의 이니셔티브에 의해 촉진되고 있습니다. 헬스케어 지출이 증가함에 따라 CIDP의 최첨단 치료, 조기 진단 및 더 나은 관리에 대한 액세스가 향상되어 이러한 모든 것이 환자 결과와 QOL 향상에 기여합니다. 예를 들어, 영국 정부 기관인 국가 통계국은 2024년 5월, 2022-2023년 총 헬스케어 지출이 5.6% 증가했다고 보고했습니다. 이러한 헬스케어 지출 증가는 CIDP 시장을 뒷받침하고 있습니다.

CIDP 시장의 주요 기업은 치료 효과를 개선하고, 환자의 결과를 개선하며, CIDP의 관리에 의해 적정한 면역조절을 제공하기 위해 면역글로불린 정주요법(IVIG) 등의 진보에 주목하고 있습니다. IVIG 요법은 건강한 기증자로부터 농축한 항체를 주입함으로써 면역계를 조절하고 자가면역질환에서 염증을 억제합니다. 예를 들면, 2024년 1월, 일본의 바이오 의약품 회사인 다케다 약품공업 주식회사는, 성인 CIDP 환자에 대한 IVIG 요법으로서 감마 가드 액제의 FDA 승인을 취득했습니다. 이 승인을 통해 장기적인 질환관리와 신경근 기능 개선을 목적으로 첫 투여 후 유지 투여에 의한 도입요법으로 사용할 수 있게 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It occurs when the immune system attacks the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination difficulties.

The primary treatment options for CIDP include intravenous immunoglobulin (IVIg), corticosteroids, plasmapheresis, physiotherapy, and other supportive therapies. IVIg is a blood-derived product containing antibodies that help regulate the immune system and treat autoimmune, immune deficiency, and inflammatory conditions. These treatments are administered through various routes, including intravenous, oral, and others. Diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Treatments are distributed through hospitals, pharmacies, online pharmacies, and specialty clinics, with key end users including hospitals, research institutions, and homecare settings.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market research report is one of a series of new reports from The Business Research Company that provides chronic inflammatory demyelinating polyneuropathy (CIDP) market statistics, including the chronic inflammatory demyelinating polyneuropathy (CIDP) industry global market size, regional shares, competitors with the chronic inflammatory demyelinating polyneuropathy (CIDP) market share, detailed chronic inflammatory demyelinating polyneuropathy (CIDP) market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (CIDP) industry. This chronic inflammatory demyelinating polyneuropathy (CIDP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be credited to the increasing geriatric population, advancements in treatment options, greater awareness and early diagnosis, progress in immunology and autoimmune research, and the rising prevalence of autoimmune diseases.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size is expected to see strong growth in the next few years. It will grow to $3.11 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be credited to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, increased patient advocacy and awareness campaigns, and advancements in healthcare infrastructure. Key trends include the rising prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, expanding research and development activities, the emergence of biosimilar therapies, and the development of personalized medicine approaches.

The increasing healthcare expenditure is expected to drive the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. The rise in healthcare spending is fueled by investments in medical infrastructure, increased demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare access. As healthcare expenditure grows, it enhances access to cutting-edge treatments, early diagnosis, and better management of CIDP, all of which contribute to improved patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a notable acceleration compared to the 0.9% growth seen in 2022. This growing healthcare expenditure is thus propelling the CIDP market.

Leading companies in the CIDP market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, enhance patient outcomes, and offer more targeted immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, with an initial dose followed by maintenance doses to manage long-term disease and improve neuromuscular function.

In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for CIDP in China. This partnership aims to provide a convenient, effective, and well-tolerated treatment, addressing unmet medical needs and improving patient outcomes. Argenx SE, a Netherlands-based biotechnology company, focuses on advancing therapies for severe autoimmune diseases, including CIDP.

Major players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., and AdvaCare Pharma.

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic inflammatory demyelinating polyneuropathy (cidp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic inflammatory demyelinating polyneuropathy (cidp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic inflammatory demyelinating polyneuropathy (cidp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Characteristics

3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends And Strategies

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Analysis And Strategic Analysis Framework

6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation

7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional And Country Analysis

8. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

9. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

10. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

11. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

12. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

13. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

14. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

15. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

16. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

17. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

18. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

20. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

21. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

22. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

24. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

26. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

27. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

28. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

29. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

30. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape And Company Profiles

31. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Other Major And Innovative Companies

32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

34. Recent Developments In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

35. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기